| Symbol | AKBA |
|---|---|
| Name | AKEBIA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 245 FIRST STREET,SUITE 1100, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 871-2098 |
| Fax | — |
| — | |
| Website | https://www.akebia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Additional info from NASDAQ: |
2026-04-15 17:09
New Form PRE 14A - Akebia Therapeutics, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001517022-26-000029 <b>Size:</b> 3 MB
Read more
2026-04-03 20:06
Vickers Philip J. 🟢 acquired 214.4K shares (1 derivative) of Akebia Therapeutics, Inc. (AKBA) at $1.41 Transaction Date: Apr 01, 2026 | Filing ID: 000005
Read more
2026-04-03 17:06
New Form 3 - Akebia Therapeutics, Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001635046-26-000004 <b>Size:</b> 9 KB
Read more
2026-04-02 20:05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-04-01 20:05
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Read more
2026-03-26 16:25
New Form SCHEDULE 13G/A - Akebia Therapeutics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000566 <b>Size:</b> 7 KB
Read more
2026-03-19 20:05
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Read more
2026-03-05 23:55
Butler John P. 🟢 acquired 69.3K shares of Akebia Therapeutics, Inc. (AKBA) at $1.25 Transaction Date: Mar 04, 2026 | Filing ID: 000003
Read more
2026-03-02 21:05
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07429006 | SAD and MAD Study of AKB-9090 in Healthy Adult Participants | Phase1 | Healthy Volunteers | Not_Yet_Recruiting | 2026-03-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT07268638 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis … | Phase2 | Focal Segmental Glomerulosclerosis | Recruiting | 2025-12-03 | 2028-01-01 | ClinicalTrials.gov |
| NCT07086755 | Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrom… | Phase2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | Recruiting | 2025-10-23 | 2026-07-01 | ClinicalTrials.gov |
| NCT06901505 | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Sta… | Phase3 | Anemia of Chronic Kidney Disease | Active_Not_Recruiting | 2025-07-24 | 2026-08-01 | ClinicalTrials.gov |
| NCT05082571 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Parti… | Phase3 | Anemia of Chronic Kidney Disease | Withdrawn | 2025-01-01 | 2026-10-01 | ClinicalTrials.gov |
| NCT05082584 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Parti… | Phase3 | Anemia of Chronic Kidney Disease | Withdrawn | 2025-01-01 | 2026-10-01 | ClinicalTrials.gov |
| NCT06520826 | Vafseo Outcomes In-Center Experience | Phase3 | Anemia of Chronic Kidney Disease | Active_Not_Recruiting | 2024-11-20 | 2026-06-30 | ClinicalTrials.gov |
| NCT05085275 | Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chro… | Phase3 | Anemia, Iron Deficiency | Completed | 2022-03-30 | 2024-01-24 | ClinicalTrials.gov |
| NCT04922645 | Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants | Phase4 | Hyperphosphatemia | Completed | 2021-06-29 | 2022-09-15 | ClinicalTrials.gov |
| NCT04707768 | Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting … | Phase3 | Anemia Associated With Chronic Kidney Disease (CKD) | Completed | 2021-06-18 | 2023-01-30 | ClinicalTrials.gov |
| NCT04478071 | Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndr… | Phase2 | Acute Respiratory Distress Syndrome | Completed | 2020-08-22 | 2022-03-25 | ClinicalTrials.gov |
| NCT04299633 | Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on th… | Phase1 | Healthy Volunteers | Completed | 2020-06-15 | 2020-09-28 | ClinicalTrials.gov |
| NCT03992066 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadus… | Phase1 | Anemia Associated With Chronic Kidney Disease | Completed | 2019-05-28 | 2020-07-15 | ClinicalTrials.gov |
| NCT03799627 | Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epo… | Phase2 | Anemia | Completed | 2019-01-31 | 2020-07-15 | ClinicalTrials.gov |
| NCT03789032 | Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadust… | Phase1 | Drug Interaction Potentiation | Completed | 2018-10-03 | 2018-11-19 | ClinicalTrials.gov |
| NCT03657290 | A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG an… | Phase1 | Healthy | Completed | 2018-08-03 | 2018-10-16 | ClinicalTrials.gov |
| NCT03801759 | Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide | Phase1 | Drug Interaction Potentiation | Completed | 2018-07-20 | 2018-09-30 | ClinicalTrials.gov |
| NCT03801746 | Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rif… | Phase1 | Drug Interaction Potentiation | Completed | 2018-07-20 | 2018-08-15 | ClinicalTrials.gov |
| NCT03801733 | Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pra… | Phase1 | Drug Interaction Potentiation | Completed | 2018-06-17 | 2018-11-24 | ClinicalTrials.gov |
| NCT03799848 | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hep… | Phase1 | Hepatic Impairment | Completed | 2018-06-12 | 2018-10-18 | ClinicalTrials.gov |
| NCT03639155 | A Study in Evaluating Bioequivalence Between Test and Reference Formulations of… | Phase1 | Healthy | Completed | 2018-04-12 | 2018-05-23 | ClinicalTrials.gov |
| NCT03254485 | A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Hear… | Phase2 | Heart Failure With Preserved Ejection Fraction | Completed | 2017-11-07 | 2019-08-19 | ClinicalTrials.gov |
| NCT03217591 | A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in D… | Phase2 | Type 2 Diabetes Mellitus With Diabetic Nephropathy | Completed | 2017-08-01 | 2019-08-20 | ClinicalTrials.gov |
| NCT03242967 | Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anem… | Phase3 | Anemia | Withdrawn | 2017-08-01 | 2018-02-12 | ClinicalTrials.gov |
| NCT03140722 | Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chr… | Phase2 | Anemia | Terminated | 2017-05-02 | 2018-03-21 | ClinicalTrials.gov |
| NCT03054350 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to … | Phase2 | Anemia | Completed | 2016-12-01 | 2018-01-24 | ClinicalTrials.gov |
| NCT03054337 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to … | Phase2 | Anemia | Completed | 2016-10-01 | 2017-08-28 | ClinicalTrials.gov |
| NCT02892149 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment … | Phase3 | Anemia | Completed | 2016-08-01 | 2020-03-30 | ClinicalTrials.gov |
| NCT02865850 | Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintena… | Phase3 | Anemia | Completed | 2016-07-01 | 2020-03-30 | ClinicalTrials.gov |
| NCT02680574 | Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment … | Phase3 | Anemia | Completed | 2016-02-01 | 2020-07-31 | ClinicalTrials.gov |
| NCT02648347 | Study to Evaluate Vadadustat for the Correction of Anemia in Participants With … | Phase3 | Anemia | Completed | 2015-12-01 | 2020-07-31 | ClinicalTrials.gov |
| NCT02502500 | Effect of AKB-6548 on the Pharmacokinetics of Celecoxib | Phase1 | Healthy Volunteers | Completed | 2015-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02412449 | Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of… | Phase1 | Healthy | Completed | 2015-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02327546 | Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548 | Phase1 | Healthy Volunteers | Completed | 2014-12-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02260193 | 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End … | Phase2 | Anemia | Completed | 2014-09-10 | 2015-07-22 | ClinicalTrials.gov |
| NCT02062203 | Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2014-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01906489 | 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney … | Phase2 | Anemia | Completed | 2013-07-23 | 2014-09-03 | ClinicalTrials.gov |
| NCT01381094 | 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney D… | Phase2 | Anemia | Completed | 2011-06-15 | 2012-02-16 | ClinicalTrials.gov |
| NCT01235936 | Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Dise… | Phase2 | Anemia | Completed | 2010-10-21 | 2011-05-01 | ClinicalTrials.gov |
| NCT04707573 | Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants Wit… | Phase2 | Chronic Kidney Disease | Completed | 2010-07-08 | 2010-09-24 | ClinicalTrials.gov |
Total clinical trials: 40
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Placebo | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Praliciguat | Other | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| AKB-9090 | DRUG | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07429006 |
| Praliciguat | DRUG | Phase PHASE2 | Focal Segmental Glomerulosclerosis | RECRUITING | NCT07268638 |
| Vadadustat 1200mg | DRUG | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Vadadustat 900mg | DRUG | Phase PHASE2 | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT07086755 |
| Erythropoiesis-Stimulating Agent (ESA) | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06901505 |
| Erythropoiesis Stimulating Agent | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06520826 |
| Ferric Citrate 1 GM Oral Tablet [AURYXIA] | DRUG | Phase PHASE3 | Anemia, Iron Deficiency | COMPLETED | NCT05085275 |
| Standard of care phosphate-lowering therapy | DRUG | Phase PHASE4 | Hyperphosphatemia | COMPLETED | NCT04922645 |
| Ferric Citrate 1 gram Oral Tablet | DRUG | Phase PHASE4 | Hyperphosphatemia | COMPLETED | NCT04922645 |
| Mircera® | DRUG | Phase PHASE3 | Anemia Associated With Chronic Kidney Disease (CKD) | COMPLETED | NCT04707768 |
| placebo | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome | COMPLETED | NCT04478071 |
| Auryxia® | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Calcium acetate | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Sevelamer carbonate | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04299633 |
| Epoetin alfa | DRUG | Phase PHASE1 | Anemia Associated With Chronic Kidney Disease | COMPLETED | NCT03992066 |
| Digoxin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Adefovir | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Furosemide | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801759 |
| Cyclosporins | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Probenecid | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Rifampin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801746 |
| Sulfasalazine | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Pravastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Atorvastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Rosuvastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Simvastatin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03801733 |
| Vadadustat TIW | DRUG | Phase PHASE2 | Anemia | COMPLETED | NCT03799627 |
| Epoetin Alfa | DRUG | Phase PHASE2 | Anemia | COMPLETED | NCT03799627 |
| Rabeprazole | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT03789032 |
| vadadustat test tablets | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03639155 |
| vadadustat reference tablets | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03639155 |
| epoetin alfa | DRUG | Phase PHASE2 | Anemia | TERMINATED | NCT03140722 |
| vadadustat | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | WITHDRAWN | NCT05082571 |
| Darbepoetin alfa | DRUG | Phase PHASE3 | Anemia | COMPLETED | NCT04313153 |
| Vadadustat | DRUG | Phase PHASE3 | Anemia of Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT06901505 |
| Celecoxib | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02502500 |
| AKB-6548 tablet, test formulation given in the fed state | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| AKB-6548 tablet, test formulation given in the fasted state. | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| AKB-6548 tablet, reference formulation given in the fasted state | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02412449 |
| Ferrous Sulfate | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02327546 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| AKB-6548 (supratherapeutic dose) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| AKB-6548 (therapeutic dose) | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02062203 |
| Placebo | OTHER | Phase PHASE1 | Healthy Volunteers | NOT_YET_RECRUITING | NCT07429006 |
| AKB-6548 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02502500 |
Total products: 57